Genethon’s Post

📢 HTID#6 News 📢   Join us at HTID#6 for a compelling discussion on "Success & Frustration: Personalized Medicine, Cell and Gene Therapy Trends"    This session will feature insights from Frédéric Desdouits (TreeFrog Therapeutics), Anne Moore, PhD (Roland Berger), Miguel Forte (Kiji Therapeutics) and David Venables (Laverock Therapeutics). Moderated by Elsy Boglioli Hofman, this session promises to delve into the latest trends and challenges in personalized medicine and advanced therapies.    Make sure not to miss out on the invaluable insights offered by these European experts !   #HTID6 #HealthcareInnovation #CellTherapy #GeneTherapy #MedicalAdvancements

Learn how fixed bed bioreactors like the Corning® Ascent® FBR System are helping to close the gap between research and manufacturing in the field of cell and gene therapy. This innovative system drastically increases capacity and yield, making it possible to produce large quantities of cells and viruses needed for therapeutic applications in a cost-efficient manner. Unlike traditional 2D surfaces, the Ascent FBR system allows adherent cells to grow in uniform 2D monolayers at high densities, greatly improving efficiency and reducing costs. Read more about it here: https://lnkd.in/g6kGS6XM #AscentFBR #CellTherapy #GeneTherapy

Less than a week to go for #EUCROF24! CROs are telling us sponsor study protocols are becoming increasingly complex and sample-intensive. What we often hear: 🏨 More sites, more patients, and strict timelines... ..... Will the kits be customized for study needs? ..... Will sites have the kits in time for FPI? ..... Are the kits easy to use? What if the site makes collection errors? 🔍 More endpoints and specialized testing. It's hard to find the right labs... ..... Is there a lab near the site to process short-stability samples in<24h? ..... Can the lab develop and validate this biomarker assay on-time? ..... Can the lab do the testing according to protocol? ✈ Thousands of samples scattered across sites, labs, and with couriers... ..... Where is sample X? Is it collected? ..... Do I have sample visibility? How will I keep the sponsor informed? ..... Can I ensure sample & data integrity? 📊 Millions of data points generated - from disparate data sources... ..... When and how will data be transferred? What about ad hoc transfers? ..... Will I have a unified dataset in time for submission? ..... Is the data accurate, consistent and usable? Sounds familiar? Stop by our booth #4 if you're open to learning more about how we help CROs and sponsors generate endpoint data for their complex trials - while preventing delays and reducing costs. #clinicalresearch #clinicaltrials #clinicaloperations

Last week, Trudy Straetemans presented at the regular floor meeting of Regenerative Medicine Utrecht. She shared insights from her invaluable work at the GMP Simulation Facility of the Innovation Center for Advanced Therapies (ICAT). 💡 During her presentation, Trudy Straetemans delved into innovative strategies aimed at optimizing the translation of cellular and gene therapy medicinal products into clinical practice. Her expertise shed light on key pathways for enhancing efficiency and efficacy in this critical process. 🔬 Follow Innovation Center for Advanced Therapies (ICAT) for more exciting updates! 🌟 #RegenerativeMedicine #Innovation #GMPsimulation #ICAT

🔍 Insights on Industrial Partnerships at Carnot Imagine : We are thrilled to share the latest communication of our partner Cellectis in Nature Communications, including results obtained in partnership with Dr Annarita Miccio and Pr Marina Cavazzana's teams from Carnot Imagine. This study unveils a non-viral gene therapy approach for sickle cell disease using TALEN® technology, achieving over 50% normal hemoglobin expression in patient-derived cells. The edited hematopoietic stem and progenitor cells show promising long-term engraftment in preclinical models, paving the way for future clinical applications. 📰 https://lnkd.in/e4AZC9zc #GeneTherapy #Biotech #SickleCellDisease #TranslationalResearch #CarnotImagine #Cellectis

Only one week until our 'Overcoming Challenges in the Industrialisation of iPSC-derived therapies' webinar! Cell and Gene Therapy Catapult's Márcia F. Mata, will be discussing examples of how we are working to address key manufacturing challenges within the allogeneic cell therapy field; developing scalable, automated, and controlled processes to help bring these pioneering advanced therapies to patients will be discussed. Register now: https://buff.ly/3y9Z5XJ #iPSC #AdvancedTherapies #CellTherapies #GeneTherapies

Advancing cell and gene therapies (CGTs) globally presents unique hurdles at every step, and Labcorp has the experience and capabilities to help you overcome them. In a recent presentation for the Korea Biomedicine Industry Association (KoBIA), Maryland Rosenfeld Franklin, PhD, vice president and enterprise head of CGT at Labcorp, discussed some of these challenges and explored their solutions. Watch the recorded webinar to learn more: https://bit.ly/cellngene #CellandGeneTherapy #CellTherapy #GeneTherapy

Our Development Head of Cell and Gene Therapy, Carolyn Sasse, recently shared her predictions on #clinicaltrial trends for the #biopharma industry in 2024 as part of Citeline’s #ScripAsks series. Explore Carolyn’s perspectives on the importance of patient centricity in clinical trials: https://bit.ly/42uY7Ae

💕 💕 Check out this #HighlyCitedPaper# by Dr.Teng Huang et al: "Treating Pulmonary Fibrosis with Non-Viral Gene Therapy: From Bench to Bedside". You can find it at: https://shorturl.at/fzORT

📰 Five patients who have received a #genetherapy to treat #Duchenne #musculardystrophy (#DMD) have demonstrated improved muscle function, Endpoints News reports. The company behind this gene therapy, REGENXBIO, said today it dosed the first patient in the pivotal part of its clinical trial for RGX-202 and it expects to apply for accelerated approval in 2026. 📢 TOMORROW, during the first day of our #ASGCTBreakthroughs24 event, Jahannaz Dastgir, DO, will present an abstract exploring the interim clinical data from RGX-202. You can still register to join us online or in Chicago to learn from this and dozens of the other abstracts covering muscular dystrophy research; register at the link in comments 👇 https://lnkd.in/gjuNknxx